Enzolytics Inc. Logo

Enzolytics Inc.

ENZC

(2.2)
Stock Price

0,00 USD

-1.82% ROA

93.13% ROE

-0.3x PER

Market Cap.

8.624.970,00 USD

-31.5% DER

0% Yield

-2940.93% NPM

Enzolytics Inc. Stock Analysis

Enzolytics Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Enzolytics Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (791.37%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (-0x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (-51%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

5 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

6 ROA

The stock's ROA (-7111.07%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Enzolytics Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Enzolytics Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Enzolytics Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Enzolytics Inc. Revenue
Year Revenue Growth
2007 0
2008 5.687 100%
2009 14.708 61.33%
2010 36.968 60.21%
2011 61.400 39.79%
2015 0 0%
2016 0 0%
2017 190.000 100%
2018 5.000 -3700%
2019 0 0%
2020 0 0%
2021 200.000 100%
2022 0 0%
2023 52.796 100%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Enzolytics Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 501.806 100%
2021 116.753 -329.8%
2022 567.874 79.44%
2023 171.609 -230.91%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Enzolytics Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 40.198
2008 394.124 89.8%
2009 936.824 57.93%
2010 2.899.647 67.69%
2011 905.148 -220.35%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Enzolytics Inc. EBITDA
Year EBITDA Growth
2007 316.603
2008 -388.437 181.51%
2009 -922.115 57.88%
2010 -6.154.894 85.02%
2011 -843.748 -629.47%
2015 -5.023.480 83.2%
2016 -45.290 -10991.81%
2017 -493.020 90.81%
2018 -1.689.930 70.83%
2019 -645.410 -161.84%
2020 -3.286.430 80.36%
2021 -1.390.380 -136.37%
2022 -2.882.040 51.76%
2023 -2.126.710 -35.52%
2024 88.280 2509.05%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Enzolytics Inc. Gross Profit
Year Gross Profit Growth
2007 0
2008 5.687 100%
2009 14.708 61.33%
2010 36.968 60.21%
2011 61.400 39.79%
2015 -19.224 419.39%
2016 -18.750 -2.53%
2017 -551.199 96.6%
2018 -11.810 -4567.22%
2019 -16.964 30.38%
2020 -16.964 0%
2021 183.036 109.27%
2022 -22.088 928.67%
2023 30.708 171.93%
2024 -22.088 239.03%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Enzolytics Inc. Net Profit
Year Net Profit Growth
2007 -421.617
2008 -425.948 1.02%
2009 -969.788 56.08%
2010 -7.513.915 87.09%
2011 -884.964 -749.06%
2015 -5.048.038 82.47%
2016 -549.592 -818.51%
2017 -57.282 -859.45%
2018 -1.757.726 96.74%
2019 920.429 290.97%
2020 -3.480.691 126.44%
2021 -669.488 -419.9%
2022 -2.941.386 77.24%
2023 -2.176.832 -35.12%
2024 -7.272 -29834.43%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Enzolytics Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 -155
2008 -119 -31.36%
2009 -257 53.91%
2010 -542 52.68%
2011 -23 -2359.09%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Enzolytics Inc. Free Cashflow
Year Free Cashflow Growth
2007 -351.278
2008 -172.837 -103.24%
2009 -372.434 53.59%
2010 -409.945 9.15%
2011 -130.142 -215%
2015 13.625 1055.17%
2016 -453.776 103%
2017 4.867.665 109.32%
2018 -3.243.339 250.08%
2019 -2.241 -144627.31%
2020 -491.014 99.54%
2021 -1.472.315 66.65%
2022 -2.660.790 44.67%
2023 -880.077 -202.34%
2024 114.840.649 100.77%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Enzolytics Inc. Operating Cashflow
Year Operating Cashflow Growth
2007 40.227
2008 -130.969 130.71%
2009 -371.366 64.73%
2010 -409.945 9.41%
2011 -130.142 -215%
2015 14.675 986.83%
2016 -453.776 103.23%
2017 4.886.161 109.29%
2018 -3.243.339 250.65%
2019 -2.241 -144627.31%
2020 -491.014 99.54%
2021 -1.306.388 62.41%
2022 -2.660.790 50.9%
2023 -880.077 -202.34%
2024 114.840.649 100.77%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Enzolytics Inc. Capital Expenditure
Year Capital Expenditure Growth
2007 391.505
2008 41.868 -835.09%
2009 1.068 -3820.22%
2010 0 0%
2011 0 0%
2015 1.050 100%
2016 0 0%
2017 18.496 100%
2018 0 0%
2019 0 0%
2020 0 0%
2021 165.927 100%
2022 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Enzolytics Inc. Equity
Year Equity Growth
2007 -302.250
2008 -709.763 57.42%
2009 -1.326.930 46.51%
2010 -572.045 -131.96%
2011 -690.579 17.16%
2015 -1.069.823 35.45%
2016 -1.643.415 34.9%
2017 -3.845.783 57.27%
2018 122.322 3243.98%
2019 -1.349.976 109.06%
2020 -5.370.325 74.86%
2021 -2.289.813 -134.53%
2022 -3.324.157 31.12%
2023 -3.562.437 6.69%
2024 -3.163.009 -12.63%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Enzolytics Inc. Assets
Year Assets Growth
2007 138.921
2008 108.429 -28.12%
2009 85.338 -27.06%
2010 152.934 44.2%
2011 112.053 -36.48%
2015 644.174 82.61%
2016 55.292 -1065.04%
2017 3.308.198 98.33%
2018 5.613.423 41.07%
2019 5.598.408 -0.27%
2020 568.412 -884.92%
2021 3.238.251 82.45%
2022 2.268.184 -42.77%
2023 361.706.609 99.37%
2024 201.689.840 -79.34%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Enzolytics Inc. Liabilities
Year Liabilities Growth
2007 441.171
2008 818.192 46.08%
2009 1.412.268 42.07%
2010 724.979 -94.8%
2011 802.632 9.67%
2015 1.713.997 53.17%
2016 1.698.707 -0.9%
2017 7.153.981 76.26%
2018 5.491.101 -30.28%
2019 6.948.384 20.97%
2020 5.938.737 -17%
2021 5.528.064 -7.43%
2022 5.592.341 1.15%
2023 365.269.046 98.47%
2024 204.852.849 -78.31%

Enzolytics Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.01
Price to Earning Ratio
-0.3x
Price To Sales Ratio
69.25x
POCF Ratio
0.01
PFCF Ratio
0.08
Price to Book Ratio
-0.35
EV to Sales
1683.15
EV Over EBITDA
-57.78
EV to Operating CashFlow
1.83
EV to FreeCashFlow
1.83
Earnings Yield
-3.3
FreeCashFlow Yield
13.29
Market Cap
0,01 Bil.
Enterprise Value
0,21 Bil.
Graham Number
0.03
Graham NetNet
-0.33

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
-31.31
ROE
0.93
Return On Assets
-0.02
Return On Capital Employed
1.59
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-29.35
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
4.77
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.78
Operating Profit Margin
-29.35
Pretax Profit Margin
-29.41
Net Profit Margin
-29.41

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.19
Free CashFlow per Share
0.19
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
1.69
Return on Tangible Assets
-0.02
Days Sales Outstanding
26.25
Days Payables Outstanding
739562.76
Days of Inventory on Hand
0
Receivables Turnover
13.9
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,01
Tangible Book Value per Share
-0.01
Shareholders Equity per Share
-0.01
Interest Debt per Share
0
Debt to Equity
-0.31
Debt to Assets
0
Net Debt to EBITDA
-55.4
Current Ratio
0.98
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-3882112
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,03 Bil.
Average Inventory
0
Debt to Market Cap
0.12

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Enzolytics Inc. Dividends
Year Dividends Growth

Enzolytics Inc. Profile

About Enzolytics Inc.

Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.

CEO
Steven Sharabura
Employee
1
Address
2000 North Central Expressway
Plano, 75074

Enzolytics Inc. Executives & BODs

Enzolytics Inc. Executives & BODs
# Name Age
1 Diana Zhabilov
Chief Financial Officer
70
2 Steven Sharabura
Chief Executive Officer
70
3 Mr. Charles S. Cotropia
President & Director
70
4 Mr. Harry H. Zhabilov Jr., BSc, McS Science
CSO & Chairman
70

Enzolytics Inc. Competitors